The Nuclear Receptor Subfamily 4 Group A Member 2 pipeline drugs market research report outlays comprehensive information on the Nuclear Receptor Subfamily 4 Group A Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Nuclear Receptor Subfamily 4 Group A Member 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Infectious Disease, and Immunology which include the indications Parkinson’s Disease, Unspecified Neurologic Disorders, Coronavirus Disease 2019 (COVID-19), and Autoimmune Disorders. It also reviews key players involved in Nuclear Receptor Subfamily 4 Group A Member 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Nuclear Receptor Subfamily 4 Group A Member 2 pipeline targets constitutes close to 12 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical, and Discovery stages are 1, 1, 2, and 5 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 2 molecule.
Nuclear Receptor Subfamily 4 Group A Member 2 overview
Nuclear Receptor Subfamily 4 Group A Member 2 is a protein that in humans is encoded by a gene NR4A2. This is a member of the steroid-thyroid hormone-retinoid receptor superfamily. The encoded protein may act as a transcription factor. NR4A2 plays a key role in the maintenance of the dopaminergic system of the brain. Mutations in this gene have been associated with disorders related to dopaminergic dysfunction, including Parkinson disease, schizophrenia, and manic depression. Misregulation of this gene may be associated with rheumatoid arthritis.
For a complete picture of Nuclear Receptor Subfamily 4 Group A Member 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
